Brief: Palvella Therapeutics Announces Positive Topline Results From Phase 2 TOIVA Clinical Trial Of Qtorin™
15/12/2025 11:19
Dec 15 (Reuters) - Palvella Therapeutics Inc PVLA.O: PALVELLA THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 TOIVA CLINICAL TRIAL OF QTORIN™ 3.9% RAPAMYCIN ANHYDROUS GEL (QTORIN™ RAPAMYCIN) FOR THE TREATMENT OF CUTANEOUS VENOUS MALFORMATIONS, A SERIOUS, RARE GENETIC DISEASE WITH NO FDA-APPROVED THERAPIES PALVELLA THERAPEUTICS INC - 73% OF PARTICIPANTS IMPROVED IN PHASE 2 TRIAL PALVELLA THERAPEUTICS INC - QTORIN™ RAPAMYCIN WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS Source text: ID:nGNXb4Bm4L Further company coverage: PVLA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palvella Therapeutics
See all newsPalvella Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Palvella Therapeutics Q2 net loss widens on higher expenses
Brief: Palvella Therapeutics Announces New Data From The Phase 2 Toiva Trial Of Qtorin™ Rapamycin In Cutaneous Venous Malformations
Brief: Palvella Therapeutics Announces Uplisting To The Nasdaq Global Market
Palvella Therapeutics' Q1 net loss widens on higher costs